Danvilostomig Biosimilar Bispecific Antibody (CTLA-4 × PD-1) for Research

Cat No.: GMP-Bios-INN-1151

Anti-CTLA4/CD152 therapeutic antibody (Pre-made Danvilostomig biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Danvilostomig (development code SI-B003) is a bispecific antibody targeting CTLA-4 and PD-1. It is developed by Sichuan Baili Pharmaceutical and SystImmune for solid tumors. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1151-1mg 1mg
GMP-Bios-INN-1151-10mg 10mg
GMP-Bios-INN-1151-100mg 100mg
GMP-Bios-INN-1151-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Danvilostomig biosimilar, Bispecific Mixed mAb and scFv, Anti-CTLA4/CD152;PDCD1/CD279/PD1 Antibody: Anti-CTLA-4/CD152/CTLA4/Cytotoxic T-lymphocyte protein 4 therapeutic antibody
INN Name Danvilostomig
Target CTLA4/CD152;PDCD1/CD279/PD1
Format Bispecific Mixed mAb and scFv
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1;na
VD LC Kappa;Kappa
Highest_Clin_Trial (Jan '20) Phase-II
Est. Status Discontinued
100% SI Structure 5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL/6rp8:HL:hl/7elx:HL;None
99% SI Structure None;None
95-98% SI Structure 7su0:HL:IM/7su1:HL;None
Year Proposed 2022
Year Recommended na
Companies Sichuan Baili Pharmaceutical;SystImmune
Conditions Approved na
Conditions Active na
Conditions Discontinued Cervical cancer;Colorectal cancer;Gastric cancer;HER2 negative breast cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Small cell lung cancer;Solid tumours;Squamous cell cancer;Urogenital cancer
Production na
Development Tech na